New incident report
Incident Report Number: 2020-2287
Registrant Reference Number: 2019-CA-000135
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: CANADA
Prov / State: ONTARIO
PMRA Registration No. 26133 PMRA Submission No. EPA Registration No.
Product Name: Hartz UltraGuard Rid Flea and Tick Dog Shampoo
Yes
Unknown
Site: Animal / Usage sur un animal domestique
Unknown
Animal's Owner
Dog / Chien
Dachshund - Standard Smooth-Haired
1
Female
0.28
30
lbs
Skin
>8 hrs <= 24 hrs / >8 h <= 24 h
>2 hrs <=8 hrs / > 2 h < = 8 h
System
Unknown / Inconnu
No
No
Unknown/Inconnu
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On 04-Aug-2019, a 15 week old, 30 pound, intact, female, Dachshund - Standard Smooth-Haired dog, in unknown condition, with concomitant medical conditions of fleas, was administered 1 application of Hartz UltraGuard Rid Flea and Tick Dog Shampoo (Pyrethrins, Piperonyl butoxide, N-Octyl Bicycloheptene dicarboximide) via the topical route by the animal owner. Approximately four hours post product administration, the dog exhibited persistent diarrhea, anorexia and hiding. The dog had not been evaluated by a veterinarian, no treatment had been performed and the clinical signs continued. Bathing with liquid dish soap was discussed as an option if the owner wished to remove the product. Veterinary evaluation was recommended due to the persistent signs reported. No further information was received in this case.
Minor
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.